Skip to main content

Gain Therapeutics, Inc.

corporate_fare Company Profile

Gain Therapeutics, Inc.

GANX·NASDAQ·Life Sciences·CIK 0001819411

We are a biotechnology company developing new small molecule drugs to treat diseases in several areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases like oncology that can be targeted through protein degradation. Our main product candidate, GT-02287, is for treating Parkinson's disease and is currently in a Phase 1b study involving people with Parkinson's disease, with or without a GBA1 mutation. We have compiled extensive preclinical data demonstrating how GT-02287 works and its safety. In preclinical models of GBA1 and idiopathic Parkinson's disease, GT-02287 has been shown to restore glucocerebrosidase (GCase) function in the lysosome, improve mitochondrial health, reduce toxic lipid substrates and toxic forms of alpha-synuclein, reduce neuroinflammation, improve survival of dopaminergic neurons, increase dopamine levels, completely restore locomotor function, improve cognition, and reduce the plasma-based neurodegeneration marker, neurofilament light chain (NfL), back to the level of healthy animals. In September 2024, we announced results from a first-in-human Phase 1 clinical trial in Australia. This trial assessed the safety, tolerability, pharmacokinetics, and food effect of GT-02287 in 72 healthy volunteers. The study included a single ascending dose part with 40 participants receiving one dose at different levels, and a multiple ascending dose part with 32 participants receiving one daily dose for 14 days at different levels. Unblinded data confirmed that single and multiple doses of GT-02287 were safe and generally well tolerated up to and including the highest planned dose levels across all age groups (approximately 15% of which were over the age of 50 years). No serious adverse events or Grade 3 (severe) adverse events were observed, and no other safety signals were detected. The pharmacokinetic profile of GT-02287 was linear across the tested dose ranges, and plasma exposures at daily doses of 7.7 mg/kg and above were within the projected therapeutic range.

Gain Therapeutics, Inc. (NASDAQ:GANX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 18 items for GANX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-10, rated 8/10. Across its 18 most recent items scored 7 or higher, the top rating is 9/10, with 14 rated 8 or above. Recent SEC coverage for GANX spans 10-Q, 8-K, 10-K.

Recent high-impact activity:

  • Gain Therapeutics 10-Q: Going Concern Warning With $11.7M Cash, Runway Into Q2 2027
  • Rexaceract Shows 12-Month Motor Stability in Parkinson's, Phase 2 Set for 1Q27
  • Gain Therapeutics Reports 12-Month Phase 1b Data Showing Motor Score Stabilization in Parkinson's
  • Gain Therapeutics Q2 2026: Going Concern Warning, $13.1M Cash, and Ongoing ATM Dilution
  • Gain Therapeutics Q2 2026: $13.1M Cash Provides Runway into Q2 2027 as Phase 2 Start Nears

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$20.16M
Diluted EPS
-$0.61
Op. Cash Flow
-$18.47M
Operating Income
-$18.71M
Cash & Equivalents
$20.84M
Total Debt
$400.95K
Debt / Equity
0.02×
Shares Outstanding
42.07M sh
Source: 10-K · filed 2026-03-26 · accession 0001104659-26-035188

Short Interest & Short Volume

5.55 days to cover

FINRA reported short interest of 3,891,227 shares in GANX as of the October 30, 2026 settlement, a 21.9% increase from the prior period — about 5.5 days to cover at its recent average daily volume. On November 20, 2026, 42.8% of GANX volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)3,891,227 shares as of October 30, 2026
Change vs prior period▲ 21.9%
Days to cover5.55 at avg daily volume of 701,695
Daily short volume (FINRA facilities)42.8% of 344,790 shares on November 20, 2026
5-day average short volume53.7%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with G →
$1 +0.06% today
52-week range · as of 2026-11-10 $0.9402 – $4.34
Market cap
$44.5M
Volume
586.3K (0.8× avg)
3-mo avg 699.3K
Live data · 2026-11-21 13:40 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed GANX - Latest Insights

GANX
Nov 10, 2026, 4:07 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.08
Real-time Price: $1.00 info
Change: -$0.080 (-7%) info
Market Cap: $44.499M info
GANX
Oct 01, 2026, 9:28 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.74
Real-time Price: $1.00 info
Change: -$0.740 (-43%) info
Market Cap: $44.499M info
GANX
Oct 01, 2026, 9:16 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.75
Real-time Price: $1.00 info
Change: -$0.7525 (-43%) info
Market Cap: $44.499M info
GANX
Aug 11, 2026, 4:07 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $2.00
Real-time Price: $1.00 info
Change: -$1.00 (-50%) info
Market Cap: $44.499M info
GANX
Aug 11, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.06
Real-time Price: $1.00 info
Change: -$1.06 (-51%) info
Market Cap: $44.499M info
GANX
Jul 16, 2026, 7:53 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.68
Real-time Price: $1.00 info
Change: -$0.680 (-40%) info
Market Cap: $44.499M info
GANX
Jun 29, 2026, 4:21 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.42
Real-time Price: $1.00 info
Change: -$1.42 (-59%) info
Market Cap: $44.499M info
GANX
Jun 29, 2026, 4:07 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $2.15
Real-time Price: $1.00 info
Change: -$1.15 (-53%) info
Market Cap: $44.499M info
GANX
May 26, 2026, 9:26 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.90
Real-time Price: $1.00 info
Change: -$0.900 (-47%) info
Market Cap: $44.499M info
GANX
May 26, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.86
Real-time Price: $1.00 info
Change: -$0.8593 (-46%) info
Market Cap: $44.499M info
GANX
May 11, 2026, 4:08 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $1.85
Real-time Price: $1.00 info
Change: -$0.850 (-46%) info
Market Cap: $44.499M info
GANX
May 11, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.82
Real-time Price: $1.00 info
Change: -$0.820 (-45%) info
Market Cap: $44.499M info
GANX
May 11, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.86
Real-time Price: $1.00 info
Change: -$0.860 (-46%) info
Market Cap: $44.499M info
GANX
Mar 26, 2026, 4:07 PM EDT
Filing Type: 10-K
Importance Score:
7
Price at Filing: $1.89
Real-time Price: $1.00 info
Change: -$0.890 (-47%) info
Market Cap: $44.499M info
GANX
Mar 26, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.89
Real-time Price: $1.00 info
Change: -$0.890 (-47%) info
Market Cap: $44.499M info
GANX
Mar 26, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.90
Real-time Price: $1.00 info
Change: -$0.900 (-47%) info
Market Cap: $44.499M info
GANX
Mar 18, 2026, 8:51 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.53
Real-time Price: $1.00 info
Change: -$1.53 (-60%) info
Market Cap: $44.499M info
GANX
Feb 03, 2026, 4:25 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.81
Real-time Price: $1.00 info
Change: -$0.810 (-45%) info
Market Cap: $44.499M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets